Lomecel-B™ is now known as laromestrocel, a cellular therapy for Alzheimer's and hypoplastic left heart syndrome, following WHO approval. Longeveron Inc. has announced that its cellular therapy ...
This marks the first time in company history that a brand name developed using the company's proprietary AI-powered name generation platform, Brandi™, has been approved by a major regulatory agency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results